clinical applications of tms copy not class slides/084.pdf · neosync. please (clinical trial site...
TRANSCRIPT
![Page 1: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/1.jpg)
Clinical Applications of TMS
&Evidence in Depression
2553480Adam Stern, M.D. Director of Psychiatric Applications
Berenson-Allen Center for Noninvasive Brain Stimulation, BIDMC
Assistant Professor of PsychiatryHarvard Medical School
PLEASE D
O NOT C
OPY
![Page 2: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/2.jpg)
Overview
• TMS Basics in Psychiatry
• TMS studies in depression
• Treatment program at BIDMC
PLEASE D
O NOT C
OPY
![Page 3: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/3.jpg)
Disclosures
Research has been previously supported by
Harvard Catalyst / The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health centers. The content is solely the responsibility of the author and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.
NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation
Neosync (Clinical Trial Site PI)
PLEASE D
O NOT C
OPY
![Page 4: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/4.jpg)
Disclosures (cont.)• TMS has been approved for treatment in
treatment-resistant depression and OCD though we may discuss other uses which have not been FDA approved.
• Some portion of the material has been shared by other members of the BA-CNBS and are used with permission.
• I have no financial conflicts to report.
PLEASE D
O NOT C
OPY
![Page 5: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/5.jpg)
What is the need for non-invasive brain stimulation?
PLEASE D
O NOT C
OPY
![Page 6: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/6.jpg)
What about Electroconvulsive therapy (ECT)?
Image courtesy of: http://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml
• Many decades of safety and efficacy data
• Gold Standard for treatment-resistant depression
• Invasive stimulation requiring anesthesia with frequent cognitive adverse effects
• Enormous stigma
PLEASE D
O NOT C
OPY
![Page 7: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/7.jpg)
A.T. Barker1984 PLE
ASE DO N
OT COPY
![Page 8: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/8.jpg)
Electro-Magnetic Induction
“I think I got hold of a good thing”
M. Faraday29 August 1831
PLEASE D
O NOT C
OPY
![Page 9: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/9.jpg)
Stimulation Coils
PLEASE D
O NOT C
OPY
![Page 10: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/10.jpg)
Topographic resolution
PLEASE D
O NOT C
OPY
![Page 11: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/11.jpg)
Stern AP, Cohen D. Neuropsychiatry 2013. PLEASE D
O NOT C
OPY
![Page 12: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/12.jpg)
Scalp to Brain Relation
PLEASE D
O NOT C
OPY
![Page 13: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/13.jpg)
Image from Nexstim.com
PLEASE D
O NOT C
OPY
![Page 14: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/14.jpg)
TMS Parameters
PLEASE D
O NOT C
OPY
![Page 15: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/15.jpg)
rTMS:Lasting Modulation of Cortical Activity
ShamTMS
TMS
1 HzTMS
20 HzTMS
Valero et al. 2002PLEASE D
O NOT C
OPY
![Page 16: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/16.jpg)
Therapeutic Applications of rTMS
• Depression• Bipolar Disorder• OCD• PTSD• Schizophrenia• Pain
– Visceral pain– Atypical facial pain– Phantom pain
• PD• Focal dystonia• Epilepsy• Stuttering• Tics• Neurorehabilitation
– Neglect– Aphasia– Hand weakness
PLEASE D
O NOT C
OPY
![Page 17: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/17.jpg)
www.brainsway.com/treatments/obsessive-compulsive-disorderPLEASE D
O NOT C
OPY
![Page 18: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/18.jpg)
Potential Adverse Effects• Common:
– Headache– Auditory effects
• Rare– Seizure induction– Effects on Cognition– Mania– Endocrine effects
PLEASE D
O NOT C
OPY
![Page 19: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/19.jpg)
rTMS in Depression
• Kolbinger et al. 1993, 95
• Grisaru et al. 1994
• George et al. 1996
• Pascual-Leone et al. 1996– Double Blind
– Multiple Control Conditions
– 17 patients
– 9/17 with ∂HDRS > 50%
Lancet 1996PLEASE D
O NOT C
OPY
![Page 20: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/20.jpg)
rTMS for depression treatmentEfficacy - Review
Gershon, Dannon and Grunhaus (Am J Psychiatry 2003; 160:835–845)
PLEASE D
O NOT C
OPY
![Page 21: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/21.jpg)
PLEASE D
O NOT C
OPY
![Page 22: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/22.jpg)
Sen-Star Treatment Link4 key functions:
* Contact sensing to ensure treatment coil is positioned correctly
* Magnetic field confirmation to ensure patient receives desired treatment
* Surface field cancellation to reduce stimulation of the scalp
* Charge approximately $100 per treatment
PLEASE D
O NOT C
OPY
![Page 23: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/23.jpg)
Stimulation Parameters
10 pulses/sec120% of motor threshold3000 pulses/session4–6 weeksIron-core coil
PLEASE D
O NOT C
OPY
![Page 24: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/24.jpg)
PLEASE D
O NOT C
OPY
![Page 25: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/25.jpg)
PLEASE D
O NOT C
OPY
![Page 26: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/26.jpg)
Phase IDrug-FreeLead-In7-10 days
Phase IIAcute Treatment Phase
6 weeks
Phase IIITaper Phase
3 weeks
Primary Timepoint @ 4 weeks
Durability of Effect @ 9 weeks
[TMS Taper + Open-label AD Mono-Rx]
Study 101 Trial DesignRandomized, Double-blind, Sham-Controlled
Secondary Timepoint @ 6 weeks
NeuroStar TMS Therapy(N=155)
Sham TMS (N=146)
Randomization
n=325
PLEASE D
O NOT C
OPY
![Page 27: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/27.jpg)
PLEASE D
O NOT C
OPY
![Page 28: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/28.jpg)
PLEASE D
O NOT C
OPY
![Page 29: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/29.jpg)
PLEASE D
O NOT C
OPY
![Page 30: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/30.jpg)
PLEASE D
O NOT C
OPY
![Page 31: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/31.jpg)
How does TMS compare to other approaches for treatment-resistant depression?
• Olanzapine/Fluoxetine (Thase, 2007): 0.33
• Aripiprazole (Marcus, 2008): 0.34
• Neurostar TMS Therapy (Demitrack, 2009): 0.52
• Brainsway DeepTMS (Levkovitz, 2015): 0.76
• Electroconvulsive Therapy (UK ECT Review Group, 2003): 0.91
PLEASE D
O NOT C
OPY
![Page 32: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/32.jpg)
Brainsway DeepTMS: A New Device
PLEASE D
O NOT C
OPY
![Page 33: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/33.jpg)
CONSORT
PLEASE D
O NOT C
OPY
![Page 34: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/34.jpg)
Levkovitz, et al. World Psychiatry 2015;14:64–73
DeepTMS HDRS Change
PLEASE D
O NOT C
OPY
![Page 35: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/35.jpg)
PLEASE D
O NOT C
OPY
![Page 36: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/36.jpg)
Is this as good as it gets? Probably Not.
Oliveira-Maia A, Press DZ, Pascual-Leone A. Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation. PLE
ASE DO N
OT COPY
![Page 37: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/37.jpg)
What about Stim. Target?
PLEASE D
O NOT C
OPY
![Page 38: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/38.jpg)
iTBS is just as effective?
Blumberger et al. 2018. Lancet.PLEASE D
O NOT C
OPY
![Page 39: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/39.jpg)
Patient Referral
• For patients with medication resistant depression
• Must be under care of psychiatrist
• Referral form on tmslab.org or call: 667-0307
PLEASE D
O NOT C
OPY
![Page 40: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/40.jpg)
Initial Evaluation
• Referral from treating psychiatrist• Neurology
– Contraindications– Effect of medication on TMS
• Psychiatry– Caution if: Psychotic depression, bipolar, personality
disorders– At least one adequate trial of antidepressant medication
PLEASE D
O NOT C
OPY
![Page 41: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/41.jpg)
PLEASE D
O NOT C
OPY
![Page 42: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/42.jpg)
Consent
• Discussion of on-label vs. off-label treatment
• Explanation of side-effects– Seizure– Headache– Neck pain– Scalp pain
PLEASE D
O NOT C
OPY
![Page 43: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/43.jpg)
Initiation Phase
• Treatments daily (excluding weekends)• Various mood assessments
daily/weekly/monthly• Minimum 2 weeks• Maximum 4-6 weeks
PLEASE D
O NOT C
OPY
![Page 44: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/44.jpg)
Assessment tools
• Beck, Hamilton, Analogue scale• Target symptoms• Clinician evaluation of patient• Other sources of information (e.g. family, referring
psychiatrist)• Side effects questionnaire
• Weekly meeting of all staff to discuss progress
PLEASE D
O NOT C
OPY
![Page 45: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/45.jpg)
Maintenance Phase
• Minimal evidence (absence of evidence, not evidence of absence)
• Relapse prevention– Start with weekly treatment– Gradually space out sessions
• “Watchful Waiting”– Patient presents when feeling worse
PLEASE D
O NOT C
OPY
![Page 46: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/46.jpg)
Alternatives being investigated
• Choosing protocol/frequency based on clinical parameters (anxiety, risk of mania/sz)
• Using rs-fMRI guidance for targeting• Using anatomical MRI to help with intensity of
stimulation (particularly in elderly)• Plasticity measures as guide• Multiple Sessions per day?
PLEASE D
O NOT C
OPY
![Page 47: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/47.jpg)
Conclusions
• TMS can be used to affect brain circuitry• TMS has potential therapeutic effects for
certain neuropsychiatric disorders • It is FDA cleared for treatment of medication
resistant depression• The future is very bright, but rigorous
investigation is required
PLEASE D
O NOT C
OPY
![Page 48: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/48.jpg)
PLEASE D
O NOT C
OPY
![Page 49: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/49.jpg)
Cost
• Insurance coverage depends on location– Medicare jurisdiction– Private payers
• Additional fee for assessments• Helping with billing, talking with payers
PLEASE D
O NOT C
OPY
![Page 50: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/50.jpg)
PLEASE D
O NOT C
OPY
![Page 51: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/51.jpg)
I am confident that I know how to refer patients for rTMS
• Mean 2.71 (3.5 is neutral)• Disagree 69.9%, Agree 30.1%
PLEASE D
O NOT C
OPY
![Page 52: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/52.jpg)
•Mean 3.76•Disagree 31.6%, Agree 68.4% (even though they don’t know how!)
I will likely refer patients for TMS in the future
PLEASE D
O NOT C
OPY
![Page 53: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/53.jpg)
• Mean 2.30• Residents 2.05, Faculty 2.52 (p<0.01)• Academic 2.20, Community 2.59 (p=0.092)
approaches significance
I am confident that TMS is covered by most insurance plans
PLEASE D
O NOT C
OPY
![Page 54: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/54.jpg)
I feel that TMS is an effective treatment for treatment-resistant depression:
• Mean 3.82
PLEASE D
O NOT C
OPY
![Page 55: Clinical Applications of TMS COPY NOT class slides/084.pdf · Neosync. PLEASE (Clinical Trial Site PI) DO NOT COPY. Disclosures (cont.) • TMS has been approved for treatment in](https://reader033.vdocument.in/reader033/viewer/2022060609/605ff9e7ee825b4af64c3a1c/html5/thumbnails/55.jpg)
•Mean 2.89
I know and understand the FDA indications for TMS use in treatment-resistant depression:
PLEASE D
O NOT C
OPY